Similar Items: Correction to “Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma”
- Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma
- Targeting Temozolomide‐Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor
- Correction to “Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells”
- Temozolomide reconsidered: Real-World evidence in resistant melanoma cases
- The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
- The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers